Drugs / Ammoxetine
Ammoxetine
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07694869 | May → Oct 2026 expected | — | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07694843 | Mar → Oct 2026 expected | — | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07508462 | May → Jun 2024 | — | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT07508501 | Feb 2023 | — | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03850834 | Mar → May 2019 | depressive disorder | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03456388 | Oct 2017 → Jul 2018 | depressive disorder | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05762458 | Feb 2023 → May 2024 | major depressive disorder | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05018013 | Aug 2021 → Aug 2022 | major depressive disorder | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06827431 | Feb 2025 → Jun 2026 overdue | major depressive disorder | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ammoxetine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03850834 ↗ |
| Known as | ammoxetine hydrochloride | “This study is a single-center, non-randomized, open-label, parallel-group, multiple-dose Phase I clinical trial evaluating the pharmacokinetic characteristics of ammoxetine...” NCT07694869 ↗2“Participants in all groups receive 20 mg of ammoxetine hydrochloride enteric-coated tablets daily at 1 hour after meals, from day 1 to day 6.” NCT07694843 ↗ “Drug: Ammoxetine Ammoxetine hydrochloride enteric-coated tablets Drug: Placebo placebo to Ammoxetine and Sertraline.” NCT06827431 ↗ |
| Known as | Ammoxetine hydrochloride enteric-coated tablets | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05018013 ↗ |
| Action | Inhibit | “Ammoxetine, a novel selective serotonin and norepinephrine reuptake inhibitor, has been found to reduce adverse effects and hepatotoxicity and more potent inhibition of...” PMID 40982284 ↗ Sep 2025 |
| Route | Oral | “single oral dose of ammoxetine hydrochloride enteric-coated tablets” NCT07508462 ↗ |